low - Elective medical procedures for severe emphysema patients are clinically driven rather than discretionary. However, hospital capital budgets for new technology adoption can be affected during recessions, potentially slowing new account additions. Patient out-of-pocket costs are minimal with Medicare coverage, reducing direct consumer spending sensitivity. The 300,000+ eligible patient population with severe disease creates consistent underlying demand regardless of economic conditions.

Rising interest rates negatively impact valuation multiples for unprofitable growth companies, as future cash flows are discounted more heavily. The company's cash balance (estimated $40-60M based on current ratio of 4.86x) earns higher returns in rising rate environments, partially offsetting operating losses. Financing costs are minimal given low debt levels (0.94x debt/equity), but future capital raises become more expensive in high-rate environments. Hospital capital equipment purchasing decisions may be delayed if healthcare systems face higher borrowing costs.

growth - Investors are betting on commercial adoption curve acceleration and path to profitability within 3-5 years. The 22% revenue growth rate and large addressable market attract growth-oriented healthcare specialists. However, the 78% one-year decline and deep losses have eliminated momentum investors. Current $100M market cap suggests only specialized small-cap healthcare funds and insiders remain. High-risk/high-reward profile given binary outcomes around Medicare policy, competitive entry, and cash runway.